Integrated Advisors Network LLC Raises Stock Position in The Clorox Company (NYSE:CLX)

Integrated Advisors Network LLC raised its stake in The Clorox Company (NYSE:CLX - Free Report) by 98.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,338 shares of the company's stock after buying an additional 2,148 shares during the period. Integrated Advisors Network LLC's holdings in Clorox were worth $639,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Wedge Capital Management L L P NC boosted its holdings in Clorox by 33.5% in the first quarter. Wedge Capital Management L L P NC now owns 28,510 shares of the company's stock worth $4,198,000 after purchasing an additional 7,159 shares in the last quarter. California Public Employees Retirement System boosted its holdings in Clorox by 1.3% in the fourth quarter. California Public Employees Retirement System now owns 565,810 shares of the company's stock worth $91,893,000 after purchasing an additional 6,987 shares in the last quarter. Rhumbline Advisers boosted its holdings in Clorox by 5.7% in the first quarter. Rhumbline Advisers now owns 273,462 shares of the company's stock worth $40,267,000 after purchasing an additional 14,647 shares in the last quarter. Deutsche Bank AG boosted its holdings in Clorox by 14.0% in the fourth quarter. Deutsche Bank AG now owns 654,198 shares of the company's stock worth $106,248,000 after purchasing an additional 80,189 shares in the last quarter. Finally, Merit Financial Group LLC boosted its holdings in Clorox by 176.9% in the first quarter. Merit Financial Group LLC now owns 6,297 shares of the company's stock worth $927,000 after purchasing an additional 4,023 shares in the last quarter. Institutional investors own 78.53% of the company's stock.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber purchased 4,000 shares of the stock in a transaction dated Wednesday, May 7th. The shares were bought at an average price of $136.57 per share, with a total value of $546,280.00. Following the completion of the transaction, the director now directly owns 4,000 shares in the company, valued at approximately $546,280. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.57% of the company's stock.

Clorox Trading Down 1.5%

Shares of CLX stock traded down $1.81 during trading hours on Tuesday, hitting $122.12. 1,273,810 shares of the company's stock traded hands, compared to its average volume of 1,361,517. The stock's 50 day simple moving average is $134.30 and its 200 day simple moving average is $147.74. The stock has a market cap of $15.05 billion, a PE ratio of 21.92, a price-to-earnings-growth ratio of 2.80 and a beta of 0.54. The Clorox Company has a 12 month low of $121.98 and a 12 month high of $171.37. The company has a quick ratio of 0.44, a current ratio of 0.74 and a debt-to-equity ratio of 13.07.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same quarter in the previous year, the business posted $1.71 earnings per share. The company's revenue for the quarter was down 8.0% compared to the same quarter last year. On average, sell-side analysts anticipate that The Clorox Company will post 7.15 EPS for the current year.

Analyst Ratings Changes

CLX has been the subject of a number of recent research reports. Barclays decreased their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a report on Wednesday, May 7th. Evercore ISI set a $140.00 target price on shares of Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. UBS Group reduced their target price on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Citigroup reduced their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research note on Monday, April 14th. Finally, Wells Fargo & Company reduced their target price on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Clorox has a consensus rating of "Hold" and an average target price of $151.23.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.